ARVINAS INC (ARVN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ARVN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ARVN | Chief Medical Officer | 62 | ["More than 20 years of experience in advancing programs through early and late stages of development","Senior Vice President Hematology Development at BMS","Held roles of increasing responsibility at Novartis, Inc.","Executive at Impath, a cancer-testing services company","Founder and Chief Executive Officer of Synvista","Trained in Medical Oncology at the National Cancer Institute","Received M.D., Ph.D. from Columbia University"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Noah Berkowitz, M.D., Ph.D., has served as our Chief Medical Officer since March 2024. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development. From January 2020 through 2023, Dr. Berkowitz was Senior Vice President Hematology Development at BMS where his teams were responsible for multiple global regulatory approvals for small molecules, biologics and cell therapies. From 2012 to 2020, while developing drugs for rare disease, oncology and hematology at Novartis, Inc., Dr. Berkowitz held roles of increasing responsibility, culminating in the role, VP Clinical Development Head, Hematology. Earlier in his career, Dr. Berkowitz was an executive at Impath, a cancer-testing services company (acquired by Genzyme), and founder and Chief Executive Officer of Synvista. Dr. Berkowitz trained in Medical Oncology at the National Cancer Institute and received his M.D., Ph.D., from Columbia University.